Our portfolio of cancer therapies is designed to redefine patient outcomes, offering minimally invasive treatment options that are backed by rigorous clinical research.
Cancer therapies backed by clinical data
With investment in research, we are advancing science to unlock the full potential of interventional oncology and help you choose the best treatment for each patient.
Our commitment to change the fight against cancer is evident in our extensive research initiatives, which include 50 global investigator-initiated studies and 14 trials exploring expanded interventional oncology indications.
>58K
Patients treated with minimally invasive cancer therapies/year*
14
Trials exploring expanded IO indications
50
Global IO investigator-initiated research studies
*Patients treated with BSC cancer therapies in 2023.
Interventional oncology for liver cancer
We're innovating every day to bring more transformative treatments and procedures that enable you to improve the patient experience and outcomes.
![hub page images - TheraSphere product](/en-EU/medical-specialties/interventional-radiology/interventional-oncology-embolisation/cancer-therapies/_jcr_content/root/container/container_947831390/container_1510545751/container_2140490311/image.coreimg.png/1717750990009/therasphere-product1.png)
TheraSphereTM is the only SIRT Y-90 CE Marked under MDR for the treatment of all hepatic malignancies and with real-world experience in over 100,000 patients.
By personalising and precisely targeting the powerful TheraSphere Y-90 dose, clinical teams around the world are achieving stunning patient outcomes –defying expectations in terms downstaging, survival rates and patient quality of life.
![Ablation](/en-EU/medical-specialties/interventional-radiology/interventional-oncology-embolisation/cancer-therapies/_jcr_content/root/container/container_947831390/container_1510545751/container_copy/image.coreimg.png/1720004825116/ablation1.png)
Backed by rigorous clinical research and unrivalled educational support, our cryoablation solutions offer visibility and control, and are challenging standards of care across a variety of cancers and painful conditions. With game-changing innovation, we’ve streamlined our technology to meet the practical and efficiency demands of your minimally invasive procedures with no compromise to performance.
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
TheraSphere is a registered trademark of Theragenics Corporation, used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.